BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36201323)

  • 1. Metastatic or xenograft colorectal cancer models induce divergent anabolic deficits and expression of pro-inflammatory effectors of muscle wasting in a tumor-type-dependent manner.
    Kim HG; Huot JR; Pin F; Belcher DJ; Bonetto A; Nader GA
    J Appl Physiol (1985); 2022 Dec; 133(6):1273-1283. PubMed ID: 36201323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LP07 and LLC preclinical models of lung cancer induce divergent anabolic deficits and expression of pro-inflammatory effectors of muscle wasting.
    Belcher DJ; Guitart M; Hain B; Kim HG; Waning D; Barreiro E; Nader GA
    J Appl Physiol (1985); 2022 Dec; 133(6):1260-1272. PubMed ID: 36201324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCT116 colorectal liver metastases exacerbate muscle wasting in a mouse model for the study of colorectal cancer cachexia.
    Huot JR; Novinger LJ; Pin F; Bonetto A
    Dis Model Mech; 2020 Jan; 13(1):. PubMed ID: 31915140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia.
    Huot JR; Novinger LJ; Pin F; Narasimhan A; Zimmers TA; O'Connell TM; Bonetto A
    JCI Insight; 2020 May; 5(9):. PubMed ID: 32298240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia.
    Huot JR; Pin F; Narasimhan A; Novinger LJ; Keith AS; Zimmers TA; Willis MS; Bonetto A
    J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1779-1798. PubMed ID: 33200567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced rDNA transcription diminishes skeletal muscle ribosomal capacity and protein synthesis in cancer cachexia.
    Kim HG; Huot JR; Pin F; Guo B; Bonetto A; Nader GA
    FASEB J; 2021 Feb; 35(2):e21335. PubMed ID: 33527503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK.
    White JP; Puppa MJ; Gao S; Sato S; Welle SL; Carson JA
    Am J Physiol Endocrinol Metab; 2013 May; 304(10):E1042-52. PubMed ID: 23531613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MC38 Tumors Induce Musculoskeletal Defects in Colorectal Cancer.
    Huot JR; Pin F; Essex AL; Bonetto A
    Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of adiponectin receptor agonist AdipoRon relieves cancer cachexia by mitigating inflammation in tumour-bearing mice.
    Massart IS; Kouakou AN; Pelet N; Lause P; Schakman O; Loumaye A; Abou-Samra M; Deldicque L; Bindels LB; Brichard SM; Thissen JP
    J Cachexia Sarcopenia Muscle; 2024 Jun; 15(3):919-933. PubMed ID: 38572511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer.
    Judge SM; Deyhle MR; Neyroud D; Nosacka RL; D'Lugos AC; Cameron ME; Vohra RS; Smuder AJ; Roberts BM; Callaway CS; Underwood PW; Chrzanowski SM; Batra A; Murphy ME; Heaven JD; Walter GA; Trevino JG; Judge AR
    Cancer Res; 2020 May; 80(9):1861-1874. PubMed ID: 32132110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered cardiac muscle mTOR regulation during the progression of cancer cachexia in the ApcMin/+ mouse.
    Manne ND; Lima M; Enos RT; Wehner P; Carson JA; Blough E
    Int J Oncol; 2013 Jun; 42(6):2134-40. PubMed ID: 23589074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic paraplegia-induced muscle atrophy downregulates the mTOR/S6K1 signaling pathway.
    Dreyer HC; Glynn EL; Lujan HL; Fry CS; DiCarlo SE; Rasmussen BB
    J Appl Physiol (1985); 2008 Jan; 104(1):27-33. PubMed ID: 17885021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
    Bonetto A; Aydogdu T; Jin X; Zhang Z; Zhan R; Puzis L; Koniaris LG; Zimmers TA
    Am J Physiol Endocrinol Metab; 2012 Aug; 303(3):E410-21. PubMed ID: 22669242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The complex heterogeneity of immune cell signatures across wasting tissues with C26 and 5-fluorouracil-induced cachexia.
    VanderVeen BN; Cardaci TD; Bullard BM; Huss AR; McDonald SJ; Muhammed AD; Kubinak JL; Fan D; Murphy EA
    Am J Physiol Cell Physiol; 2024 Feb; 326(2):C606-C621. PubMed ID: 38189130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C26 cancer-induced muscle wasting is IKKβ-dependent and NF-kappaB-independent.
    Cornwell EW; Mirbod A; Wu CL; Kandarian SC; Jackman RW
    PLoS One; 2014; 9(1):e87776. PubMed ID: 24489962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexia.
    Judge SM; Wu CL; Beharry AW; Roberts BM; Ferreira LF; Kandarian SC; Judge AR
    BMC Cancer; 2014 Dec; 14():997. PubMed ID: 25539728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation.
    Quan-Jun Y; Yan H; Yong-Long H; Li-Li W; Jie L; Jin-Lu H; Jin L; Peng-Guo C; Run G; Cheng G
    Mol Cancer Ther; 2017 Feb; 16(2):334-343. PubMed ID: 27599525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tumor burden and subsequent surgical resection on skeletal muscle mass and protein turnover in colorectal cancer patients.
    Williams JP; Phillips BE; Smith K; Atherton PJ; Rankin D; Selby AL; Liptrot S; Lund J; Larvin M; Rennie MJ
    Am J Clin Nutr; 2012 Nov; 96(5):1064-70. PubMed ID: 23034966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia.
    Ham DJ; Murphy KT; Chee A; Lynch GS; Koopman R
    Clin Nutr; 2014 Jun; 33(3):448-58. PubMed ID: 23835111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrine improves skeletal muscle atrophy by inhibiting E3 ubiquitin ligases and activating the Akt/mTOR/FoxO3α signaling pathway in C2C12 myotubes and mice.
    Chen L; Chen L; Wan L; Huo Y; Huang J; Li J; Lu J; Xin B; Yang Q; Guo C
    Oncol Rep; 2019 Aug; 42(2):479-494. PubMed ID: 31233199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.